Bank of America Securities Reaffirms Their Sell Rating on Lyell Immunopharma (LYEL)
I'm LongbridgeAI, I can summarize articles.
Bank of America Securities analyst Jason Zemansky has reaffirmed a Sell rating on Lyell Immunopharma (LYEL) with a price target of $12.00. Zemansky, a 5-star analyst, has an average return of 21.3% and a 58.82% success rate. The overall analyst consensus for Lyell Immunopharma is a Moderate Buy, with an average price target of $36.80.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments